US Pharma MarketingAvalo’s phase 2 skin disease win fuels pursuit of AbbVie despite placebo headwind
Avalo’s phase 2 skin disease win fuels pursuit of AbbVie despite placebo headwind is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
The placebo-adjusted result fell short of the bar set by Avalo, analysts and AbbVie’s rival program, but the biotech’s stock jumped in premarket trading.
Source: FierceBiotech